2025-09-19 - Analysis Report
Okay, here's an analysis of TEM (Unknown Company) based on the provided data, presented in a structured format with key metrics, comparisons, and insights.

**1. Performance vs. S&P 500 (VOO)**

*   **Company Overview:** Tempus AI is an Unknown Company (as stated in the prompt).
*   **Cumulative Return (TEM):** 57.68%
*   **Cumulative Return (VOO):** 25.57%
*   **Absolute Divergence:** 32.4
*   **Relative Divergence:** 45.1
    *   The cumulative return of TEM significantly outperforms the S&P 500 (VOO) by 32.4%.  The Relative Divergence of 45.1 indicates that TEM's outperformance is in the lower half of its historical range compared to VOO. This suggests while the stock has outperformed, there's been more extreme outperformance periods in the past.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD   | Alpha | Beta | Cap(B) |
|------------|--------|-------|-------|------|--------|
| 2023-2025  | 58.0%  | 75.0% | 33.0% | -0.0 | 15.1   |

*   **CAGR:** The Compound Annual Growth Rate is very high at 58.0%.
*   **MDD:** The Maximum Drawdown is also very high at 75.0%, indicating substantial risk and volatility.
*   **Alpha:** A positive Alpha of 33.0% suggests the stock has outperformed its benchmark on a risk-adjusted basis.
*   **Beta:** A Beta of -0.0 indicates very little correlation with the overall market (S&P 500). It suggests TEM's price movements are largely independent of the market.
*   **Cap(B):** Market capitalization is 15.1 billion.

**2. Recent Stock Price Movement**

*   **Current Price:** $87.07
*   **Previous Close:** $86.45
*   **Change:** +$0.72
*   **5-Day Moving Average:** $86.41
*   **20-Day Moving Average:** $80.22
*   **60-Day Moving Average:** $68.22

*   **Analysis:** The stock is trading above all its moving averages, indicating a short-term, medium-term, and long-term uptrend.  The price increased slightly from the previous close, suggesting continued positive momentum. The change of $0.72 is not big enough to indicate a dramatic spike or sharp fall.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.3324 (Low Risk)
*   **RSI:** 71.77 (Overbought territory - potentially indicating the stock is due for a correction.)
*   **PPO:** 0.2116 (Positive and relatively high, further supporting the upward trend.)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
    *   The Hybrid Signal suggests using 80% of available cash to buy shares, with a note of caution due to the MRI.
*   **Delta (20-Day Relative Divergence):** +7.1 (Indicates a recent increase in outperformance relative to the S&P 500.)
*   **Expected Return:** NaN (No data provided, can't assess long-term potential.)

**4. Recent News & Significant Events**

*   **FDA Clearances:** Multiple news items highlight FDA clearances for Tempus AI's cardiac imaging platform (Pixel) and radiology portfolio.
*   **Partnerships:** Collaboration with Renalytix to improve kidney disease risk assessment.
*   **Market Growth:** Positive outlook for the global cell therapy market.
*   **Price Surge:**  Reports of the stock hitting a 7-month high.
*   **Analysis:** The news is overwhelmingly positive, focusing on regulatory approvals, strategic partnerships, and market expansion. This news likely contributed to the recent stock price appreciation.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.15)
*   **Number of Opinions:** 11
*   **Target Price:** $73.45 (Average), $98.00 (High), $60.00 (Low)
*   **Analysis:**  Analyst consensus is positive ("Buy"). However, the current stock price of $87.07 is *above* the average target price of $73.45, suggesting the stock may be overvalued according to the average analyst estimate. The high target price ($98.00) indicates some analysts are more optimistic. The lack of recent rating changes information limits deeper analysis.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 예상 EPS |
|------------|--------|----------|
| 2025-08-08 | -0.22  | -0.23    |
| 2025-05-06 | -0.24  | -0.26003 |
| 2025-02-24 | -0.18  | -0.15    |
| 2024-11-04 | -0.25  | -0.26608 |
| 2024-08-06 | -0.63  | -0.59    |

*   **Analysis:** The company is consistently reporting negative EPS (Earnings Per Share), indicating it is not currently profitable. However, in most recent quarters, the reported EPS has *exceeded* expectations. The EPS is still negative, but improving compared to last year. The big negative earnings for 2024-08-06 could be an area to investigate.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
|--------------|-------------|---------------|
| 2025-06-30   | $0.31B      | 61.99%         |
| 2025-03-31   | $0.26B      | 60.69%         |
| 2024-12-31   | $0.20B      | 60.83%         |
| 2024-09-30   | $0.18B      | 58.50%         |
| 2024-06-30   | $0.17B      | 45.50%         |

**Capital and Profitability:**

| Quarter      | Equity      | ROE          |
|--------------|-------------|--------------|
| 2025-06-30   | $0.31B      | -13.84%       |
| 2025-03-31   | $0.33B      | -20.86%       |
| 2024-12-31   | $0.06B      | -23.10%       |
| 2024-09-30   | $0.05B      | -141.16%      |
| 2024-06-30   | $0.10B      | -562.04%      |

*   **Revenue:** Revenue is growing consistently over the past five quarters.
*   **Profit Margin:** Profit margins are very strong, consistently above 60% in recent quarters, an indicator of strong pricing power.
*   **Equity:** Equity has fluctuated, with a significant increase in 2025.
*   **ROE:** Return on Equity is consistently negative, reflecting the lack of overall profitability despite strong revenue and profit margins.  The extremely negative ROE figures in 2024 suggest significant losses relative to equity.

**7. Summary Analysis**

TEM (Unknown Company) is a high-growth, high-risk stock showing strong revenue growth and impressive profit margins but currently reporting negative earnings. The company has significantly outperformed the S&P 500, but its high MDD indicates substantial volatility. Recent FDA approvals and strategic partnerships are positive catalysts. Analyst consensus is "Buy," but the current stock price is above the average target price. While revenue and profit margins are strong, the negative ROE figures and negative EPS should be considered. Overall, TEM is a speculative investment that could yield high returns, but investors should be aware of the significant risks involved.
